• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Approval No. 5 for Avastin


You can officially add Avastin to the list of targeted drugs approved for kidney cancer. Genentech just reported that the Food and Drug Administration has approved Avastin (bevacizumab) plus interferon for patients with metastatic renal cell carcinoma, the most common type of kidney cancer. (Check out our feature on kidney cancer from the current Summer issue.) That's the fifth cancer for which the FDA has deemed Avastin worthy of its stamp of approval. Just this past May, the regulatory agency greenlighted the drug for a type of brain tumor called glioblastoma multiforme, and before that, Avastin was OKed for metastatic colorectal cancer, non-small cell lung cancer, and metastatic breast cancer. (Its first approval came in 2004.)We'll cover the approval in more detail in the upcoming Fall issue, which drops in September.

Related Videos
A man with a dark gray button-up shirt with glasses and cropped brown hair.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE